Status:
TERMINATED
Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
Detailed Description
Acamprosate has been an available treatment for alcohol dependence outside the United States and has recently been approved by the U.S. Food and Drug Administration as an effective therapy for alcohol...
Eligibility Criteria
Inclusion
- History of alcohol dependence in the year before entering criminal justice supervision
- Currently under criminal justice supervision (drug court, probation, or parole) in central Virginia
Exclusion
- Pregnant or nursing a baby
- Known sensitivity to acamprosate
- Elevated serum creatinine level or other evidence of kidney problems
- Symptoms of severe depression or suicidal ideation
- Non-English speaking such that they cannot provide informed consent
- Cognitive impairment such that they cannot provide informed consent
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00249379
Start Date
June 1 2005
End Date
August 1 2008
Last Update
May 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23219